Edgewise Therapeutics, Inc. (EWTX) Balance Sheet

The sequential decline in total assets, from $613.3M in 2025Q2 to $479.7M in 2026Q2, reflects the company's ongoing investment in late-stage trials without corresponding revenue. The equity base has contracted by 16% over the same period, driven by net losses that averaged over $50M per quarter. This trajectory suggests that the balance sheet is being depleted to fund the GRAND CANYON pivotal trial, with no near-term catalyst to reverse the trend absent external financing.

The negligible debt level indicates a conservative capital structure, but it also means the company has no financial leverage to cushion operational losses. With quarterly cash burn exceeding $40M, the current cash position provides less than two quarters of runway, implying that additional equity issuance is likely. This could dilute existing shareholders, a risk that is not captured by the low D/E ratio.

The steady decline in PPE suggests minimal capital expenditure, consistent with a biotech that outsources manufacturing and relies on contract research organizations. The absence of goodwill indicates that all growth has been organic, with no acquisition-related intangibles. This asset mix implies that the company's value is tied to its pipeline's success, making the balance sheet less informative about future cash flows than clinical milestones.

The widening accumulated deficit is a direct result of pre-revenue operations, with net losses exceeding $50M per quarter. Despite this, equity remains substantial due to prior fundraising, but the trend indicates that without new capital, equity will continue to erode. The lack of share repurchases or dividends suggests all resources are directed toward R&D, which is typical for a clinical-stage company but heightens dilution risk.

The high current ratio is misleading because it is driven by a small liability base, not by robust cash reserves. With quarterly cash burn exceeding $40M, the company has limited liquidity to absorb shocks or delays in trial enrollment. The cash position improved from $33.2M in 2026Q1 to $72.3M in 2026Q2, likely due to a capital raise, but this is a temporary buffer that will be consumed by ongoing R&D expenditures.